Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

[The influence of solar and geomagnetic activity on the risk of multiple sclerosis (results of correlation and regression analysis)].

Samoylova NA, Shkilnyuk GG, Goncharova ZA, Stolyarov ID.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):42-49. doi: 10.17116/jnevro20171172242-49. Russian.

PMID:
28617360
2.

[Clinical recommendations on the use of teriflunomide].

Alifirova VM, Bakhtiyarova KZ, Belova AN, Bisaga GN, Boiko AN, Boiko OV, Vlasov YV, Volkova LI, Goncharova ZA, Davydovskaya MV, Zakharova MN, Kotov SV, Lashch NY, Malkova NA, Petrov AM, Popova EV, Sivertseva SA, Sokolova IA, Spirin NN, Stolyarov ID, Streknev AG, Totolyan NA, Khachanova NV, Sherman MI, Shmidt TE, Khabirov FA, Yampol'skaya-Gosteva IA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10. Vyp. 2):98-104. doi: 10.17116/jnevro201611610298-104. Russian. No abstract available.

PMID:
28139617
3.

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators.

Neurology. 2016 Nov 8;87(19):1985-1992. Epub 2016 Oct 12.

4.

[Capabilities of positron emission tomography to study mecha-nisms of multiple sclerosis: own data and literature].

Stolyarov ID, Petrov AM, Shkilnyuk GG, Kataeva GV, Prakhova LN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(2 Pt 2):27-31. doi: 10.17116/jnevro20161162227-31. Russian.

PMID:
27070358
5.

[The role of the solar and geomagnetic activity in the etiology of multiple sclerosis: a review of the literature and prospects of research].

Stolyarov ID, Goncharova ZA, Shkilnyuk GG, Samoylova NA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(2 Pt 2):5-13. doi: 10.17116/jnevro2016116225-13. Russian.

PMID:
27070355
6.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

O'Connor P, Comi G, Freedman MS, Miller AE, Kappos L, Bouchard JP, Lebrun-Frenay C, Mares J, Benamor M, Thangavelu K, Liang J, Truffinet P, Lawson VJ, Wolinsky JS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group and the MRI-AC in Houston, Texas.

Neurology. 2016 Mar 8;86(10):920-30. doi: 10.1212/WNL.0000000000002441. Epub 2016 Feb 10. Erratum in: Neurology. 2016 Oct 4;87(14 ):1524.

7.

[Regional metabolic changes of supraventricular tissue in patients with relapsing-remitting and secondary-progressive multiple sclerosis].

Bogdan AA, Ilves AG, Kataeva GV, Prakhova LN, Trofimova TN, Stolyarov ID.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(8. Vyp. 2):14-17. doi: 10.17116/jnevro20151158214-17. Russian.

PMID:
28635709
8.

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, Montalban X, Boyko AN, Comi G; ALLEGRO Study Group.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):851-8. doi: 10.1136/jnnp-2013-306132. Epub 2013 Sep 12.

PMID:
24029546
9.

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.

Wolinsky JS, Narayana PA, Nelson F, Datta S, O'Connor P, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Miller A, Freedman MS; Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group.

Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27.

PMID:
23447359
10.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
11.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
12.

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.

Arch Neurol. 2012 Oct;69(10):1259-69.

PMID:
22751847
13.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
14.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
15.

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group.

N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318.

16.

Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease.

Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.

Clin Neuropharmacol. 2012 Mar-Apr;35(2):67-72. doi: 10.1097/WNF.0b013e31824523de.

PMID:
22377973
17.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group.

N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.

18.

Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.

Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN.

J Clin Pharmacol. 2012 Jul;52(7):1069-77. doi: 10.1177/0091270011409232. Epub 2011 May 24.

PMID:
21610205
19.

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.

Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M; FORTE Study Group.

Ann Neurol. 2011 Jan;69(1):75-82. doi: 10.1002/ana.22316.

PMID:
21280077
20.

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.

Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group.

Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8.

PMID:
20834039

Supplemental Content

Loading ...
Support Center